In Parkinson disease (PD), a-synuclein aggregates called Lewy bodies often involve and sequester Septin4 (Sept4), a polymerizing scaffold protein. However, the pathophysiological significance of this phenomenon is unclear. Here, we show the physiological association of Sept4 with a-synuclein, the dopamine transporter, and other presynaptic proteins in dopaminergic neurons; mice lacking Sept4 exhibit diminished dopaminergic neurotransmission due to scarcity of these presynaptic proteins. These data demonstrate an important role for septin scaffolds in the brain. In transgenic mice that express human a-synuclein A53T (a mutant protein responsible for familial PD), loss of Sept4 significantly enhances neuropathology and locomotor deterioration. In this PD model, insoluble deposits of Ser 129 -phosphorylated a-synuclein A53T are negatively correlated with the dosage of Sept4. In vitro, direct association with Sept4 protects a-synuclein against self-aggregation and Ser 129 phosphorylation. Taken together, these data show that Sept4 may be involved in PD as a dual susceptibility factor, as its insufficiency can diminish dopaminergic neurotransmission and enhance a-synuclein neurotoxicity.
INTRODUCTION
Septins are polymerizing GTP binding proteins that serve as scaffolds for diverse molecules beneath the plasma membrane (Field and Kellogg, 1999; Versele and Thorner, 2005; Kinoshita, 2006) . In addition to playing roles in mitosis (Kinoshita et al., 1997 , Surka et al., 2002 Spiliotis et al., 2005) , mammalian septins are abundant in the central nervous system (CNS) (Kinoshita et al., 1998 (Kinoshita et al., , 2000 Xue et al., 2004; Hall et al., 2005) , where they have been implicated in exocytosis (Hsu et al., 1998; Beites et al., 1999 Beites et al., , 2005 Xue et al., 2004) . However, it is not clear whether and how septins are involved in exocytosis and/or neurotransmission in vivo, partly because mice that lack Sept3, Sept5, or Sept6 do not show obvious CNS abnormalities (Fujishima et al., 2007; Peng et al., 2002; Ono et al., 2005) .
Meanwhile, septins have been implicated in diverse neurodegenerative disorders in humans. For instance, mutations in the Sept9 gene were found in hereditary neuralgic amyotrophy (Kuhlenbaumer et al., 2005) . Sept4 and two other septins were found in neurofibrillary tangles in Alzheimer's disease (Kinoshita et al., 1998) . Sept4 coaggregates with a-synuclein in cytoplasmic inclusion bodies known as Lewy bodies (LBs) in sporadic Parkinson disease (PD) and dementia with Lewy bodies and in glial cytoplasmic inclusions in multiple system atrophy (Ihara et al., 2003) . Sept4 and Sept5/CDCrel-1 are substrates for a ubiquitin ligase, parkin; hence, loss of parkin function may result in accumulation of these paralogous septins (Zhang et al., 2000b; Choi et al., 2003; Son et al., 2005) . Intriguingly, acute overload of Sept5 can be both inhibitory to exocytosis and neurotoxic (Beites et al., 1999; Dong et al., 2003; Son et al., 2005) . However, it is not clear whether the toxicity of septin overload or loss of septin function plays important roles in the pathogenesis of a-synucleinopathies.
This study was designed to address physiological and pathological roles of Sept4 in normal and PD brains. We first examined the status of Sept4 in sporadic PD cases and found that it was often deficient in dopaminergic (DA) nerve terminals in the striatum. This prompted us to explore the consequences of Sept4 deficiency in Sept4 À/À mice, and our comprehensive screening pinpointed a specific attenuation of their nigrostriatal DA transmission without affecting the neuronal morphology. We found that Sept4 is required for DA neurons to maintain key components of DA metabolism. Transgenic supplementation of Sept4 was sufficient to rescue the biochemical deficits in Sept4 À/À striatum. Finally, we tested whether Sept4 deficiency could modify a-synucleinopathy in transgenic mice expressing human a-synuclein A53T , a pathogenic mutant responsible for a trait of familial PD (Giasson et al., 2002) . Surprisingly, genetic loss of Sept4 in this PD model exacerbated neuronal loss, gliosis, and locomotor deterioration, which were accompanied by severe amyloid deposits containing Ser 129 -phosphorylated a-synuclein
A53T
. In vitro, Sept4 interfered with selfaggregation and Ser 129 phosphorylation of a-synuclein. These results suggest that physiological interaction with Sept4 prevents a-synuclein from converting into neurotoxic species and aggregates, and that DA neurons deficient in Sept4 become more susceptible to further dysfunction and degeneration in PD.
RESULTS

Physiological Localization of Sept4 in Presynaptic Dopaminergic Terminals in Human Striatum and Its Depletion in Parkinson Disease
In agreement with our previous observations (Ihara et al., 2003) , antibodies raised against three distinct epitopes of Sept4 consistently labeled LBs in the substantia nigra pars compacta (SNpc) of all sporadic PD cases examined (n = 5; Figures 1B and 1D, and data not shown). Sept4 and a-synuclein colocalized in the core of LBs (Figures 1C and 1D) , indicating their close relationship. In contrast, antibodies for five other septins including Sept5/CDCrel-1 (a substrate for parkin) did not label LBs ( Figure 1A and data not shown). These data confirmed the specific involvement of Sept4 in a-synuclein aggregates in PD.
In control human brains without PD, Sept4 was abundant in presynaptic terminals of DA neurons projecting from SNpc to the striatum (putamen). Sept4 was colocalized in the varicosities with the dopamine transporter (DAT in Figures 1E-1G ) and a-synuclein (aS in Figures 1H-1J ). These data suggest physiological association of Sept4 with these presynaptic molecules in DA nerve terminals.
To examine the status of presynaptic Sept4 in PD, we measured the content of Sept4 in the putamen by immunohistochemistry and immunoblot. In non-PD controls, immunohistochemical signals for Sept4 were more intense in the putamen than in the adjacent cerebral (insular) cortex ( Figures 1K and 1S) , while in PD, Sept4 was recognizably reduced in the putamen ( Figures 1L and 1S ). The deficiency of Sept4 was comparable with that of DAT in the adjacent slices ( Figures 1Q and 1R ). The relative densitometric values for Sept4 in the putamen (Dpu) and insular cortex (Dcx) could segregate PD cases from non-PD controls ( Figure 1M , n = 12). In contrast, a general presynaptic marker, synaptophysin, was not reduced in PD putamen ( Figures 1N-1P , n = 8). Consistently, immunoblot analysis demonstrated that Sept4 was often reduced in PD specifically in the putamen but not in the cerebral cortex ( Figures 1T-1W and Figure S1 in the Supplemental Data). Considering the heterogeneous etiology of sporadic PD and the variability of individual human samples, Sept4 deficiency in the striatum is regarded as one of the common pathological changes in PD.
Loss of Sept4 Attenuates Dopaminergic Transmission in the Mouse
To address the physiological significance of Sept4 in the CNS, we examined the distribution of Sept4 and the impact of its loss in the mouse. Using in situ hybridization and immunohistochemistry techniques, it was demonstrated that Sept4 was expressed in specific cell populations in the cerebral cortex, striatum, midbrain, cerebellum, and spinal cord (Figures 2A-2E , Figure S9 , and data not shown). As with DA neurons, Sept4 was present in the cell bodies in the SNpc and ventral tegmental area (VTA) ( Figure 2D ), in projection fiber bundles (arrows in Figures 2B and 2E) , and in axon terminals surrounding striatal neurons ( Figure 2E ). As seen in the human brain, Sept4, a-synuclein, and DAT were abundant and colocalized in the axon terminals, especially at the varicosities ( Figures 2F-2K ).
We generated Sept4 À/À mice with a genetic background of C57BL/6J, all of which appeared normal except for unexpected male infertility . All the Sept4 polypeptides were abolished in Sept4 À/À brain (Figures 2A-2C ). Given the widespread distribution of Sept4 in the CNS, we performed a comprehensive physical and behavioral screening (Supplemental Figures S2-S5 ).
Sept4
À/À mice were normal except for a paradigm of prepulse inhibition of the acoustic startle response (PPI). This paradigm is an index of reduction in startle amplitude to a loud acoustic stimulus when the stimulus is preceded by a moderate prestimulus ( Figure 3A ). Sept4 À/À mice exhibited a lower basal startle response and a significant enhancement in PPI ( Figure 3B ; p = 0.0011). Since DA antagonists can enhance PPI (Zhang et al., 2000a) , we suspected attenuated DA transmission in Sept4 À/À mice. The mice were challenged with apomorphine at a low dose (0.05 mg/kg) that is known to block DA transmission by selectively stimulating DA presynaptic autoreceptors (Starke et al., 1989) . PPI was enhanced in Sept4 +/+ mice but disrupted in Sept4 À/À mice (the differences between Figures   3B and 3C are indexed in Figure 3D ). However, a higher dose of apomorphine (3 mg/kg), which dominantly stimulates postsynaptic DA receptors, disrupted PPI in both genotypes (Supplemental Figure S6) . Thus, the attenuated DA transmission in Sept4 À/À mice was attributed to presynaptic (rather than postsynaptic) defects.
To confirm this, we reassessed spontaneous locomotor activity in an open field (as in Supplemental Figure S5 ) with methamphetamine, which releases DA from the presynaptic terminals (Hyman et al., 2006) . While the basal activity and methamphetamine-driven hyperactive surge were almost normal in Sept4 À/À mice, their hyperactivity decayed more rapidly ( Figure 3E , p < 0.05). These data indicate a presynaptic cause of the attenuated DA transmission in Sept4 À/À striatum.
In addition, DA content was significantly reduced in Sept4 À/À striatum by $25% ( Figure 6G ; p = 0.039), indicating a requirement of Sept4 for DA metabolism.
Dopaminergic Axon Terminals in Sept4
À/À Striatum Are Morphologically Normal but Deficient in Key Molecules for Dopamine Metabolism Based on the behavioral pharmacology data, we examined the status of nigral DA neurons by immunohistochemistry for tyrosine hydroxylase (TH), the rate-limiting enzyme of DA synthesis. In the midbrain, the number and morphology of TH-positive neuronal somata were comparable between Sept4 +/+ and Sept4 À/À mice (Supplemental Figure S7 ). However, Sept4 À/À striatum was labeled less intensely for TH and DAT ( Figure 4A ). Quantitative morphometric analyses of TH/DAT-positive axons and axon terminals at both the light microscopy level ( Figure 4B ) and EM level ( Figure 4C and Supplemental Figure S8 ) could not discriminate the two genotypes. In immunoblot, the densitometric ratios of TH and DAT against synapsin IIa or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were significantly reduced in Sept4 À/À striatum (by $30% and $55%, respectively), The densitometric ratio of Sept4/GAPDH was not reduced in the cerebral cortices of the PD patients. These data also exclude a possibility that Sept4 is subject to postmortem protein degradation.
but not in the ventral midbrain (Figures 4D-4G ; data not shown). However, five postsynaptic parameters we examined were unaffected ( Figures 4H and 4I , Figure 6D , and data not shown). cDNA driven by the prion promoter. The heterozygous Tg mice were lean ($25% body weight reduction), shortlived, and barely fertile. These defects seemed to be due to the nonspecific cytotoxicity of Sept4 overload (Ihara et al., 2003; Dong et al., 2003) and ectopic Sept4 expression in the heart, adrenal gland, and germ cells (see Discussion). Crossbreeding of Sept4-Tg1 and Sept4
mice rarely generated live Sept4KO/Tg1 mice that expressed Sept4 54 kDa and shorter processed forms in the striatum. Sept4KO/Tg1 striatum contained normal levels of TH and DAT (Figures 5A and 5B) . Although Sept4KO/ Tg2 mice were never born, Sept4-Tg2 mice showed hyper-dopaminergic behaviors ( Figures 5C and 5D ) and supernormal levels of TH and DAT (data not shown).
Although the primary effects from the loss or excess of Sept4 may be complicated by compensatory and adaptive changes, these data consistently indicate a positive role for Sept4 in DA metabolism.
Sept4 Is Required as a Component of the Presynaptic Machinery for DA Turnover
To determine the molecular mechanism underlying the hypo-dopaminergic phenotype of Sept4 À/À mice, we immunoprecipitated striatal homogenates of Sept4 +/+ mice with anti-Sept4 antibodies, then immunoblotted for possible Sept4-interacting molecules. Consistent with our previous report (Ihara et al., 2003) and the colocalization data (Figures 1G and 1J and Figures 2H and 2K) , Sept4 was coimmunoprecipitated with DAT and a-synuclein ( Figures  6A and 6B ). Since Sept5, the closest paralog of Sept4, has been implicated in syntaxin (Stx)-mediated exocytosis (Beites et al., 1999) , we tested the interaction between these septins and Stx-1A. Sept5 and Stx-1A were coimmunoprecipitated from the cerebellar cortex, but not from the striatum (data not shown). In contrast, Sept4 and Stx-1A were reciprocally coimmunoprecipitated from the striatum ( Figures 6A and 6C ). However, a component of the exocyst complex, Sec8, and a postsynaptic protein, mGluR1, were present in the striatum but did not immunoprecipitate with Sept4 ( Figure 6A ). These data indicate a physiological association of Sept4 with presynaptic molecules involved in DA release and reuptake. Given the individual associations between a-synuclein and DAT (Lee et al., 2001) , and Stx-1A and DAT ( Lee et al., 2004) , our results point to a larger protein complex in the striatum that contains Sept4, a-synuclein, Stx-1A, and DAT. Septins often serve as scaffolds that anchor and/or stabilize other molecules. Depletion of cellular septins by RNAi reduces the amount of binding partners in the same complex (Kinoshita et al., 2002) . Thus, we examined whether the loss of Sept4 also affects interaction partners other than DAT. In Sept4 À/À striatum, the contents of Stx-1A, SNAP25, Munc18, and a-synuclein were slightly but consistently reduced, while that of Vesl-1L, a postsynaptic protein, was not affected ( Figures 6D-6F ). (Note: we predict the deficiencies of Stx-1A and a-synuclein in DA neurons were underestimated by this method; these molecules are also expressed in other cells that do not express Sept4, and are hence unaffected by the loss of Sept4.) The biochemical evidence, along with the colocalization and behavioral data, strongly suggests that Sept4 is closely associated with the key molecules for DA metabolism. Considering the normal morphology of Sept4 À/À DA neurons (Figures 4B and 4C and Supplemental Figure S8 ), Sept4 may be required not as a cytoskeletal protein, but as a component of a presynaptic scaffold that directly or indirectly supports the molecular machinery for dopamine turnover.
Loss of Sept4 Exacerbates Neuropathology of a-Synuclein
A53T Transgenic Mice Next, we focused on pathological interaction between Sept4 and another molecule in the DA terminals, a-synuclein. We have so far demonstrated their physiological association and pathological coaggregation in a-synucleinopathies (Ihara et al., 2003; and Figures 1B-1D, Figure 2H, and Figures 6A, 6B, 6D, and 6F) . To critically test whether the interaction with Sept4 promotes or suppresses aggregation and neurotoxicity of a-synuclein, we utilized Sept4 À/À mice. We also employed a transgenic mouse model of a-synucleinopathy, in which human asynuclein A53T (a mutant protein responsible for a trait of familial PD) is expressed by the prion promoter (Giasson et al., 2002) . As reported, biallelic a-synuclein A53T transgenic mice (aS tg mice) developed locomotor deterioration, i.e., hindlimb paralysis followed by quadriparesis, and died within a week after the onset of the symptom. All the symptomatic animals examined exhibited a-synuclein pathology throughout the neuraxis. Of note, Sept4 involvement in a-synuclein aggregates was visualized in this model of a-synucleinopathy ( Figure 7A ). We examined consequences of genetic loss of Sept4 in aS tg mice. Unlike non-Tg mice that lived more than 24 months with or without Sept4, aS tg mice lacking Sept4 resistant to digestion by proteinase K ( Figure 7C , top panels, and Supplemental Figure S11 
Sept4 Can Suppress Pathological Modifications of a-Synuclein In Vivo
To analyze the molecular basis of the enhancement of a-synuclein pathology by the loss of Sept4, we examined the biochemical status of a-synuclein in graded extraction (i.e., in Triton-soluble, sodium dodecyl sulfate-[SDS-] soluble, and SDS-insoluble fractions) of the spinal cord. In each fraction of young asymptomatic mice, a-synuclein was detected mainly as the native form of $17 kDa (aS in Figure 7E , left top panel). Intriguingly, the SDS-insoluble fraction of aged, symptomatic mice additionally contained putative crosslinked dimers [(aS) 2 ] and other modified forms, high-molecular-weight smears (HMWaS), and aggregates that stuck at the top of the resolving gel (arrow in Figure 7E , right top panel). These aberrant a-synuclein Figure 7E , right top panel). The modified a-synuclein species were reminiscent of those found in human a-synucleinopathies; i.e., the $24 kDa band may correspond to O-glycosylation (Shimura et al., 2001) or another modification (Tofaris et al., 2003) , and the $40 kDa double bands may represent crosslinked homodimers and/or other modified species (Kahle et al., 2001 ). None of these modified species were labeled for ubiquitin (data not shown). aS not only in the spinal cord, but also in the forebrain (data not shown) and the nigral DA neurons in the midbrain (Figures 7F-7H ).
Taken together, aggregation and Ser 129 phosphorylation of a-synuclein seem to be central events underlying the neurodegeneration of aS tg mice, and these pathological modifications were obviously enhanced by the loss of Sept4.
Direct Interaction with Sept4 Prevents
Self-Aggregation and Ser 129 Phosphorylation of a-Synuclein In Vitro How does Sept4 suppress neurotoxicity caused by chronic overload of a-synuclein? It has been hypothesized that self-aggregation of a-synuclein that occurs in various pathological processes generates neurotoxic species (Dawson and Dawson, 2003) , and that Ser 129 phosphorylation can facilitate the process (Fujiwara et al., 2002 ). Thus, we tested in vitro whether these modifications could be suppressed by Sept4. First, we confirmed that a-synuclein and Sept4 directly associate in vitro ( Figure 8A ). Second, we found that Sept4 suppressed self-aggregation of a-synuclein A53T into SDS-resistant HMW species (Figure 8B) . Third, Sept4 partially interfered with Ser 129 phosphorylation of a-synuclein A53T by a ubiquitous Ser/Thrkinase, casein kinase II (CKII; Fujiwara et al., 2002) ( Figure 8C ). However, Sept4 did not essentially inhibit the kinase activity of CKII when casein was used as the substrate (Supplemental Figure S13) . When the data were taken together, we concluded that direct interaction with Sept4 can prevent a-synuclein from self-aggregation (as has been proposed for another LB component, aBcrystallin) (Rekas et al., 2004) , and may shield a-synuclein from Ser 129 phosphorylation by CKII and other kinases.
Such protective effects on a-synuclein modifications, perhaps by steric hindrance and/or conformational changes, may be more effective in the physiological situation where Sept4, DAT, and Stx-1A are in close proximity to asynuclein ( Figure 6A ).
DISCUSSION
Sept4
À/À Mice Revealed a Physiological Septin Function in the Brain
Septins have been implicated in exocytosis based on their presynaptic localization (Kinoshita et al., 2000; Xue et al., 2004) , physical and functional interaction with syntaxins (Beites et al., 1999 (Beites et al., , 2005 , and aberrant exocytosis in blood platelets lacking Sept5 (Dent et al., 2002) . However, previous attempts to address septin functions in the brain with Sept3 À/À , Sept5
, or Sept6 À/À mice were unsuccessful, probably due to compensation by their functionally redundant paralogs (Fujishima et al., 2007; Peng et al., 2002; Ono et al., 2005) . We employed a comprehensive behavioral test as a means of unbiased screening for neurological defects in Sept4 À/À mice. This approach has successfully pinpointed a specific neurological phenotype by the loss of septin function, i.e., the attenuation of nigrostriatal DA transmission. While DA neurons were functionally affected by the loss of Sept4, non-DA neurons were unchanged. This intriguing form of selectivity may be due to the absence of redundant septin species, and/ or a specific requirement of Sept4 subunit, in DA neurons.
Sept4 Is Required as a Component of Presynaptic Scaffolds in DA Neurons
Extending our previous finding of Sept4 involvement in LBs (Ihara et al., 2003) , the present study has revealed Sept4 insufficiency in presynaptic DA terminals in the human striatum affected with sporadic PD. This is partly due to sequestration of Sept4 into a-synuclein aggregates, and partly as a result of neuronal loss. To investigate the pathophysiological impact of Sept4 depletion in PD, we created and investigated several mouse models: the genetic loss of Sept4 attenuated, an excess of Sept4 enhanced, and a transgenic Sept4 supplementation of Sept4 null mice normalized nigrostriatal DA transmission. These results suggest a positive role for Sept4 in dopamine turnover. The hypo-dopaminergic behavioral deficits observed in Sept4 À/À mice were attributed not to morphological anomalies of DA neurons but to an insufficiency of specific components in DA terminals. The levels of DAT, TH, a-synuclein, Stx-1A, and another tSNARE component depended more or less on the amount of Sept4. Sept4 directly or indirectly interacts with most of these molecules in the striatum. Considering the physical association of these molecules, Sept4 can be regarded as a pivotal component of the presynaptic scaffold for the machinery of dopamine release and reuptake. The detailed organization of such machinery would be an intriguing subject for future studies. aS is absent in normal presynaptic terminals and prone to form aggregates in vitro (Fujiwara et al., 2002) . Our data suggest that Sept4 and a-synuclein are components of presynaptic complexes at the DA terminals, and that lack of the physiological association with Sept4 facilitates self-aggregation and Ser 129 phosphorylation of a-synuclein.
How Is Sept4 Involved in a-Synucleinopathy?
This study demonstrated that aS tg and aS tg /S4 À/À mice provide important insights into the biochemical processes underlying a-synucleinopathies. We have demonstrated that endogenous Sept4 is involved in a-synuclein aggregates formed in aS tg mice ( Figure 7A ) as well as humans with sporadic PD (Ihara et al., 2003 ; Figure 1B-1D ). The increased a-synuclein aggregation in aS tg /S4 À/À mice indicates that Sept4 incorporation is a secondary event that can suppress further a-synuclein aggregation. Based on these and other findings, we propose a model for a-synucleinopathies ( Figure 8D ), whereby incipient a-synuclein aggregates formed in DA neurons adsorb Sept4. This may retard LB formation, but it eventually depletes Sept4 from the presynaptic terminals ( Figure 1K-1U ). As seen in aS tg
/S4
À/À mice, Sept4 insufficiency attenuates DA transmission and subjects a-synuclein to toxic conversions. Thus, pathological a-synuclein/Sept4 interaction in LBs and dissociation of their physiological interaction at presynaptic terminals may constitute a vicious cycle that further disrupts homeostasis of DA neurons in PD. Intriguingly, DA neurons in aS tg mice developed a-synuclein aggregates only in the absence of Sept4 ( Figures  7F-7H) . Thus, loss of Sept4 is a critical event for the development of a-synuclein pathology in DA neurons, although it appears additional insults and/or aging are necessary for them to die. When compared with mice, human DA neurons are more sensitive to various insults, including a-synuclein overload (LaVoie et al., 2005; Moore et al., 2005) . Thus, Sept4 depletion found in humans ( Figures 1K-1U) should impact DA neurons more seriously.
Loss of Sept4 Function versus Gain of Toxic Effects
Sept4-Tg1 and Sept4-Tg2 transgenic mice generated in this study have demonstrated that mild chronic overload of Sept4 is cytotoxic to various cell lineages. This is consistent with previous findings that acute Sept5 overexpression can damage DA neurons in the rat (Dong et al., 2003) . Thus, both insufficiency and excess of Sept4 could perturb the homeostasis of DA neurons, ultimately leading to disorganization of their presynaptic terminals-another intriguing similarity to a-synuclein (Abeliovich et al., 2000; Chandra et al., 2005; Moore et al., 2005) . As for sporadic PD cases, however, we have not obtained any samples that contained excessive Sept4 in the striatum. Thus, Sept4 overload may not be relevant in the etiology of sporadic PD.
In summary, our present as well as previous studies have established physiological and pathological roles of Sept4 in the nigral DA neurons. Future studies should characterize the presynaptic complex containing Sept4 and other key molecules. From a pathological aspect, unraveling the precise molecular mechanism by which Sept4 suppresses the a-synuclein toxicity may help develop neuroprotective strategies for PD.
EXPERIMENTAL PROCEDURES
Analyses of Clinical Samples
Postmortem human brain tissues were dissected within 6 hours postmortem under signed informed consent from the patients' relatives, and in accordance with the guidelines of ethics committees of Kyoto University and Juntendo University. Tissues for immunohistochemistry were fixed at Kyoto University Hospital. Donor subjects included 16 PD , or BSA in PBS were ultracentrifuged at 440,000 3 g for 30 min. The supernatant (S) and the pellet (P) of each mixture were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue (CBB).
(From left to right lanes) aS alone was soluble (S). Most of Sept4 was sedimented (P), perhaps due to homo-oligomerization. aS interacted with Sept4 and interfered with the sedimentation. BSA, another soluble protein used as a control, did not show such effects. These data indicate direct association between Sept4 and aS. The same reactions were immunobloted for total aS. After 44 hr incubation without Sept4, a fraction of aS was self-aggregated or oligomerized as HMW bands. In contrast, HMW bands of aS were not formed in the presence of Sept4. A 34 kDa band (*) represents aS dimers formed in E.coli (Masuda et al., 2006 aS is more prone to self-aggregation than aS (compare the rightmost lanes of B and C). Parallel reactions using wild-type aS (instead of aS A53T ) gave similar results (data not shown). Data in (A)-(C) are representative of at least three experiments. (D) A working model of PD pathophysiology including Sept4 as a novel player: a-synuclein aggregates (LB) formed by various pathological causes commonly involve Sept4. The involvement may retard the process while it sequesters and depletes Sept4 from DA nerve terminals in the striatum. The insufficiency of Sept4 in the presynaptic scaffold reduces the critical components for DA transmission, which contributes to DA dysfunction. In addition, an excess of a-synuclein in the absence of Sept4 facilitates its oligomerization, phosphorylation, and other modifications, which generate neurotoxic species. Figure S1 for clinical data). In each case, the clinical diagnosis was confirmed neuropathologically, mostly by the presence of nigral LBs by hematoxylin-eosin stain. For immunohistochemistry, the brains fixed with 4% paraformaldehyde were sliced coronally, and the cerebral region containing the basal ganglia was isolated and embedded in paraffin, sectioned (6 mm thick), and subjected to immunohistochemistry as previously described (Ihara et al., 2003) . The immunostained sections were optically scanned (16 bit, 600 dpi), and the integrated densities for a selected area (2 mm 3 2 mm) were calculated with software (MultiGauge 2.0, Fujifilm, Japan). In each sample, three or more areas of the putamen and insular cortex were measured to obtain the average densitometric values. 
Comparative Morphometric Analyses of DA Nerve Terminals at Light Microscopy and EM Levels
High-contrast images of TH-stained mouse striatal sections were captured and digitized by a light microscope with a CCD camera. The digital images were binarized with an arbitrary threshold, and the total length of the TH-positive neurites was calculated using Neurocyte Image Analyzer, ver. 1.5 (Kurabo, Japan). For the EM-level measurement of DA nerve terminal area, we used immuno-EM images of TH and DAT. TH-or DAT-positive areas in each digital EM image displayed on a computer screen were encircled manually using a digital pen tablet system, Intuos3 (Wacom Technology, Japan). The total encircled area was automatically calculated with graphic software (Scion, ver. b 4.0.2.). For each marker, 24 fields from corresponding regions of dorsal striata of Sept4 +/+ and Sept4 À/À littermates were randomly sampled and analyzed blindly.
Immunoblotting and Immunoprecipitation
For immunoblotting, striatal tissues punched out from coronal brain slices of 3-5 m.o. mice were homogenized and sonicated in buffer A (10 mM Tris-HCl [pH 7.6], 1% Triton X-100, 0.15 M NaCl, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate), and then centrifuged at 15,000 3 g at 4 C for 0.5 hr. The protein content of the supernatants was quantified using the Bradford method, and 50 mg of protein was denatured with an equal volume of 2 3 SDS sample buffer and subjected to a standard immunoblot assay using peroxidase-conjugated secondary antibodies and an ECL chemiluminescence kit (GE Healthcare Biosciences). The amount of immunoreactive proteins was estimated by densitometry (see above). For coimmunoprecipitation of proteins, tissues were extracted with buffer B (0.1 M Tris-HCl [pH 7.6], 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, protease inhibitors). After centrifugation, the supernatants were diluted with nine volumes of lysis buffer B 0 without Triton X-100, resulting in a final concentration of 0.1%. Each lysate was incubated with various antibodies and Affi-Prep Protein A beads (Bio-Rad) at 4 C for 1 hr. Immunoprecipitates on the beads were washed five times with lysis buffer A, and analyzed by immunoblot.
Animals and Experimental Design
All animal procedures were performed in accordance with the guidelines of the Animal Use and Care Committee of Kyoto University. Heterozygous Sept4 +/À mice were backcrossed with C57BL/6J for at least ten generations Biallelic Tg mice were identified by real-time PCR analysis and verified by backcrossing. All comparisons were made between littermates to minimize confounding effects by different genetic backgrounds. All behavioral tests were carried out on male mice (2-2.5 m.o.) (Miyakawa et al., 2001) . Mice were given a light/dark cycle of 12 hr (lights on at 7 a.m.) and food and water ad libitum. Behavioral testing was performed between 9 a.m. and 6 p.m. except for the home cage social interaction test. After each test, all apparatuses were cleaned with acidic hypochlorous solution that eliminated mouse odors. Mouse brains were dissected after deep anesthesia with sodium pentobarbital (50 mg/kg, i.p.) with or without transcardial perfusion with 0.01 M phosphate-buffered saline (PBS). For histological analysis, mice were additionally perfused with 4% paraformaldehyde and 0.2% picric acid in 0.1 M PBS. Tissues from symptomatic aS tg mice were dissected within a few days after the onset of hindlimb paresis to prevent suffering for ethical reasons and to minimize temporal changes that might influence the results.
Biochemical Fractionation of Neural Tissues by Graded Extraction
The forebrain, brainstem, and spinal cord from aS tg /S4 +/+ or aS tg / S4 À/À mice (5-16 m.o.) were dissected, weighed, and homogenized by sonication in 3 ml/g of buffer C (10 mM Tris-HCl [pH 7.6], 0.15 M NaCl, 1% Triton X-100, and protease inhibitors). The supernatant, after centrifugation at 15,000 3 g at 4 C for 0.5 hr, was labeled as ''Tritonsoluble fraction.'' The pellet was sonicated and re-extracted with 1 ml/g of buffer D (10 mM Tris-HCl [pH 8.0], 0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS) and fractionated by centrifugation at 15,000 3 g at 4 C for 0.5 hr, and the supernatant was labeled as ''SDS-soluble fraction.'' The pellet was dissolved by sonication and boiling in buffer E (3% SDS and 5% b-mercaptoethanol, 1 ml/g pellet), and the lysate was termed ''SDS-insoluble fraction.'' The amounts proportional to the original brain weight were loaded on separate lanes and each fraction was analyzed by immunoblot.
In Vitro Sedimentation, Aggregation, and Phosphorylation Assays The recombinant His 6 -tagged mouse Sept4 54 kDa was prepared in Sf9 cells (Kinoshita et al., 2002) . For recombinant mouse Sept4 48 kDa , GSTfusion protein was expressed in E.coli with a plasmid, pGEX-6P (GE Healthcare Biosciences). After purification of GST-Sept4 48 kDa with glutathione-agarose beads, GST-PreScission protease (Roche) was added to the beads to cleave the GST tag and release untagged Sept4 48 kDa . For sedimentation assay, 20 ml reactions of recombinant human aS (wild-type, 4 mg, BioMol), recombinant mouse Sept4 54 kDa (2 mg), and/or BSA (2 mg, Sigma) in PBS were incubated at 4 C for 16 hr. Each reaction was ultracentrifuged at 4 C at 440,000 3 g for 30 min. The supernatants and the pellets were analyzed by SDS-PAGE/CBB. For self-aggregation and phosphorylation assays, recombinant human aS (A53T mutant, 100 mg, BioMol) was incubated in 100 ml reactions of 30 mM Tris-HCl (pH 7.5) and BSA (100 mg, Sigma) or recombinant Sept4 48 kDa (20 mg) at 37 C. For phosphorylation assays, 4 mM MgCl 2 , 2 mM ATP, and CKII (500 U, New England Biolabs) were added. The reactions sampled at 0, 2, and 44 hr were analyzed by SDS-PAGE/CBB, and analyzed by immunoblot for aS or pSer 129 aS.
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